AI-generated summary
This review of optical and pharmacological myopia treatments in children reports that low-dose atropine (0.01%) was the most effective option in its comparison, with minimal side effects. The authors state that pirenzepine, apomorphine and 7-methylxanthine need further validation, and that low-level red-light therapy and DOT lenses show promise but their long-term safety and mechanisms remain unclear.
- Who or what was studied
- Children with myopia
- Limits stated in the abstract
- The abstract states that long-term safety and efficacy of several interventions remain under investigation and that some agents have only been tested in animal models or need broader clinical testing.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
The full abstract is not shown here because it is protected by the publisher’s copyright. Read it on e-century.us.
Record from PubMed, a service of the National Library of Medicine.
How to read a review: what to check before relying on this kind of research.
Terms in this paper: Myopia, Dose. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.